Cowen Starts Audentes Therapeutics (BOLD) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Wedbush Starts Audentes Therapeutics (BOLD) at Outperform
August 15, 2016 7:14 AM EDTWedbush initiated coverage on Audentes Therapeutics (NASDAQ: BOLD) with an Outperform rating and a price target of $20.
"BOLDs AAV-based gene therapy programs are targeted to address significant unmet medical need in life-threatening rare diseases. With clinical readouts expected in 2017 from three wholly-owned... More
